STAT+: With new colon cancer study results, Mirati lays claim to best KRAS-blocking drug
A drug from Mirati Therapeutics designed to block the cancer protein called KRAS shrank tumors in 22% of patients with advanced colon cancer, according to results from a clinical trial presented Sunday.
When the Mirati drug, a pill called adagrasib, was combined with another targeted medicine, the colon cancer response increased to 43%.
Continue to STAT+ to read the full story…
